

Potential late adverse effects of chemotherapy

Drug received	Potential late adverse effect	Protocol
All chemotherapy	Impaired quality of life	1
	Secondary malignancy	2
	Transfusion-associated complications	3
	Dental caries	8
	Pigmented skin lesions	23
	Impaired immunity against vaccine-preventable infections	E
Actinomycin D	Hepatic dysfunction	18
Amsacrine	Cardiac dysfunction	14
Asparaginase	No specific late adverse effect known	
BCNU (carmustine)	Secondary leukaemia	2
	Gonadal dysfunction	11, 12
	Respiratory dysfunction	15
	Renal dysfunction	20
Bleomycin	Respiratory dysfunction	15
Busulphan	Secondary leukaemia	2
	Gonadal dysfunction	11, 12
	Respiratory dysfunction	15
	Hepatic dysfunction	18
Carboplatin	Auditory dysfunction	7
	Renal dysfunction	20
CCNU (lomustine)	Secondary leukaemia	2
	Gonadal dysfunction	11, 12
	Respiratory dysfunction	15
	Renal dysfunction	20
Chlorambucil	Secondary leukaemia	2
	Gonadal dysfunction	11, 12
Cisplatin	Peripheral neuropathy	4
	Auditory dysfunction	7
	Gonadal dysfunction	11, 12
	Renal dysfunction	20
Cyclophosphamide	Secondary leukaemia	2
	Gonadal dysfunction	11, 12
	?Cardiac dysfunction	14
	Bladder dysfunction	21
Cytarabine	Neuropsychological dysfunction	5
	Gonadal dysfunction	11, 12
Dacarbazine	Secondary leukaemia	2
	Gonadal dysfunction	11, 12
Daunorubicin	Cardiac dysfunction	14
Doxorubicin	Cardiac dysfunction	14
Epirubicin	Cardiac dysfunction	14
Estramustine	Secondary leukaemia	2
	Gonadal dysfunction	11, 12

Etoposide (VP-16)	Secondary leukaemia	2
Fludarabine	No specific late adverse effect known	
Hydroxyurea	No specific late adverse effect known	
Idarubicin	Cardiac dysfunction	14
Ifosfamide	Secondary leukaemia	2
	Gonadal dysfunction	11, 12
	Renal dysfunction	20
	Bladder dysfunction	21
	?Reduced bone mineral density	22
Melphalan	Secondary leukaemia	2
	Gonadal dysfunction	11, 12
	Renal dysfunction	20
Mercaptopurine	No specific late adverse effect known	
Methotrexate	Neuropsychological dysfunction	5
	Hepatic dysfunction	18
	Renal dysfunction	20
	?Reduced bone mineral density	22
Methyl-CCNU (semustine)	Secondary leukaemia	2
	Gonadal dysfunction	11, 12
	Renal dysfunction	20
Mitozantrone	Cardiac dysfunction	14
Mustine	Secondary leukaemia	2
	Gonadal dysfunction	11, 12
Nitrogen mustard	Secondary leukaemia	2
	Gonadal dysfunction	11, 12
Procarbazine	Secondary leukaemia	2
	Gonadal dysfunction	11, 12
Steroids	Visual dysfunction (cataract)	6
	Reduced bone mineral density	22
Teniposide (VM-26)	Secondary leukaemia	2
Thalidomide	Peripheral neuropathy	4
Thioguanine	Hepatic toxicity	18
Thiotepa	Secondary leukaemia	2
	Gonadal dysfunction	11, 12
Vinblastine	No specific late adverse effect known	
Vincristine	Peripheral neuropathy	4

NB This Table is not intended to be inclusive of all late adverse effects of chemotherapy conditioning for BMT – see Appendix B